Brief: Sensei Biotherapeutics Presents Trial-In-Progress Poster For Phase 1/2 Clinical Study Of Sns-101 At Esmo 2023
23/10/2023 13:11
Oct 23 (Reuters) - Sensei Biotherapeutics Inc SNSE.O :
* SENSEI BIOTHERAPEUTICS PRESENTS TRIAL-IN-PROGRESS POSTER
FOR
PHASE 1/2 CLINICAL STUDY OF SNS-101 AT ESMO 2023
Source text for Eikon: ID:nGNX6bz4Jv
Further company coverage: SNSE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Faeth Therapeutics,
See all newsBrief: Sensei Biotherapeutics Announces Name Change To Faeth Therapeutics
Brief: Sensei Biotherapeutics Doses First Patient In Phase 1B/2 Trial Of Piktor In Hr+/Her2- Advanced Breast Cancer
Brief: Sensei Biotherapeutics Reports Full Year 2025 Financial Results And Provides Corporate Update
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)